Northwest Biotherapeutics (NWBO) Short term Debt (2015 - 2025)

Northwest Biotherapeutics' Short term Debt history runs 11 years deep, the most recent figure standing at $9.4 million for Q4 2025.

• On a quarterly basis, Short term Debt fell 1.69% year-over-year to $9.4 million in Q4 2025; TTM through Dec 2025 was $9.4 million, a 1.69% decrease from a year earlier, with the FY2025 full-year figure at $9.4 million, down 1.69% from the prior year.
• Short term Debt retreated to $9.4 million in Q4 2025 per NWBO's latest filing, from $9.7 million in the prior quarter.
• Across five years, Short term Debt topped out at $9.7 million in Q3 2025 and bottomed at $7.6 million in Q2 2024.
• The 5-year median for Short term Debt is $8.7 million (2022), against an average of $8.8 million.
• Across the five-year window, Short term Debt gained 28.07% in 2021 and retreated 12.67% in 2024, its largest moves.
• Year by year, Short term Debt stood at $8.2 million in 2021, then advanced by 5.3% to $8.7 million in 2022, then grew by 6.0% to $9.2 million in 2023, then increased by 4.24% to $9.6 million in 2024, then slipped by 1.69% to $9.4 million in 2025.
• Per Business Quant, the three latest NWBO Short term Debt figures stand at $9.4 million (Q4 2025), $9.7 million (Q3 2025), and $9.1 million (Q2 2025).